Secnizol DS (secnidazole)
/ Incepta Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
99
Go to page
1
2
3
4
December 07, 2025
Secnidazole and Metronidazole in the Treatment of Trichomoniasis: Comparative Study of the Mechanism of Action and Development of Innovative 3D Printed Intrauterine Devices.
(PubMed, Microb Pathog)
- "The drug-loaded devices represent a promising strategy for localized and personalised treatment. This is the first proof-of-concept for a 3D-printed IUD loaded with secnidazole and metronidazole demonstrating trichomonacidal action and highlighting a novel, localized drug delivery strategy with potential applications in personalized medicine for the treatment of trichomoniasis."
Journal • Infectious Disease • Long-acting Reversible Contraceptives
November 10, 2025
A Systematic Review about the Efficacy of Antiparasitic Agents in the Treatment of Blastocystis Species.
(PubMed, Acta Parasitol)
- "Our findings suggest that metronidazole may be inappropriate as a first-line treatment, as it can increase the number of viable parasites and promote their transformation into apoptosis-resistant granular or more pathogenic amoeboid forms. Alternative agents-such as ronidazole, satranidazole, and C17 (2-position 5-nitroimidazoles), as well as ornidazole, secnidazole, and tinidazole (1-position 5-nitroimidazoles with different side chains compared with metronidazole)-show potential efficacy. Trimethoprim-sulfamethoxazole and nitazoxanide have also demonstrated promising results. Further studies, particularly subtype-specific and human clinical trials, are needed to assess the safety and efficacy of these alternative agents against Blastocystis spp."
Journal • Review • Dermatology • Immunology • Urticaria
September 16, 2025
Metronidazole Induced Fixed Drug Eruption
(ACAAI 2025)
- "This occurred one day after starting metronidazole for vulvovaginal trichomoniasis. Metronidazole is the most common and readily available drug to treat trichomoniasis in the United States. Cross reactivity with other nitroimidazoles such as tinidazole and secnidazole is variable, and patients can reasonably receive a trial of another drug in the class or undergo provocation testing to find the most suitable alternative."
Immunology • Infectious Disease • Inflammation
August 30, 2025
A Retrospective Review of Antibiotic Infusion for Symptomatic Blastocystis hominis and Dientamoeba fragilis Infections
(ACG 2025)
- "The standard infusion combination (furazolidone, nitazoxanide, secnidazole) given to 47 patients (30.5%) had a success rate of 97.87%. Of those included in the study 92 (59.7%) had Blastocystis only, 31 (20.1%) had Dientamoeba only, and 31 (20.1%) had both. All patients were symptomatic with the most common symptoms being bloating (n=114, 77%), diarrhoea (n=105, 70.9%), flatulence (n=107, 72.3%), abdominal discomfort (n=95, 64.2%), and fatigue (n=93, 62.8%). The overall success rate was 95.45%."
Retrospective data • Review • Fatigue • Gastroenterology • Gastrointestinal Disorder • Infectious Disease
October 10, 2025
Longitudinal high prevalence of intestinal parasites in preschool children despite anti-parasitic treatment in urban Colombia
(ASTMH 2025)
- "Our study seeks to determine the prevalence of intestinal parasites in preschool children in an impoverished neighborhood in Medellín, Colombia, and how infection changes after a dose of secnidazole, an antiprotozoal medication used to treat protozoa...These data highlight the high reinfection rate of intestinal parasites in a preschool population in an urban Colombian city and is further proof of the high prevalence of giardiasis in Colombia. Our study provides evidence supporting reinfection with intestinal parasites is common in preschool age and the use of anti-protozoal treatment does not reduce the prevalence."
Clinical • Infectious Disease
October 17, 2025
Design of sulfonic acid-functionalized hyper cross-linked polymer as a mixed-mode sorbent for nitroimidazoles detection.
(PubMed, Food Chem)
- "Leveraging its strong ExEf, NDF-TPE-HCP was integrated into a solid-phase extraction system coupled with HPLC for the analysis of NDZs (metronidazole, ronidazole, secnidazole, dimetridazole and ornidazole) in water and fish muscle...The method recoveries ranged from 85.2 % to 118.0 %, with the relative standard deviation (RSD) ≤ 9.8 %. The NDF-TPE-HCP based method can serve as a robust and sensitive tool for monitoring NDZs residues."
Journal
October 13, 2025
Critical Considerations on the Proposed In Vitro Secnidazole Susceptibility Breakpoint for Trichomonas vaginalis.
(PubMed, Sex Transm Dis)
- "that determines an in vitro minimal lethal concentration (MLC) of 12.5 μg/ml for secnidazole (SEC) as linked to clinical resolution in Trichomonas vaginalis [1]. Recognizing the significance of establishing SEC susceptibility thresholds with increasing metronidazole (MTZ) resistance, we highlight several critical limitations: (1) No pharmacokinetic-pharmacodynamic (PK-PD) validation correlating the MLC with attainable drug concentrations in genital tissue; (2) Omission of isolates from males even with their roles in morbidity/reservoirs; (3) Neglect of the impact of vaginal microbiota on drug-parasite dynamics; (4) Absence of analysis on molecular resistance mechanisms; and (5) Possible selection bias due to the low representation of clinical SEC failures (n = 5) and MTZ-resistant isolates (n = 1)."
Journal • Preclinical
October 01, 2025
Microfluidic paper-based fluorescent sensing device using citric acid derived carbon dots-tungsten sulfide spheres for on-site detection of secnidazole.
(PubMed, Biosens Bioelectron)
- "The detection efficiency of the sensor is validated by the World Health Organization (WHO) recommended LC-MS and UPLC methods. As indicated by the recoveries from UPLC, LC-MS, and N-CDs@WS2-based sensing device, the proposed sensor can quantitaively analyze secnidazole in real samples."
Journal • Infectious Disease • Vaginitis
July 23, 2025
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Series of 11 Cases
(EADV 2025)
- "The most frequently implicated drugs were allopurinol, hydroxychloroquine, and lamotrigine, each accounting for 18% of cases, followed by antibiotics (including sulfonamides, secnidazole, cephalexin, cefotaxime, and amoxicillin), each responsible for 9.1% of cases. SJS and TEN are rare but severe cutaneous drug reactions that can be life-threatening. Further studies are needed to clarify prognostic factors and optimize therapeutic strategies."
Clinical • Acute Kidney Injury • Bullous Pemphigoid • Dermatopathology • Immunology • Nephrology • Renal Disease • Steven-Johnson Syndrome
July 23, 2025
Drug Profile of Severe Toxicodermias in the Dermatology Department, Bab El Oued University Hospital, Algiers
(EADV 2025)
- "The most commonly implicated drugs in DRESS patients were antibiotics (38.88%) (amoxicillin +/− clavulanic acid, cefotaxime, ciprofloxacin, vancomycin, Bactrim, and azithromycin), followed by aromatic antiepileptics (33.33%) (carbamazepine, phenobarbital, lamotrigine, sodium valproate), and allopurinol (3 cases, 16.7%), with sulfasalazine and acetazolamide. In patients with Stevens-Johnson syndrome/Lyell's syndrome or a combination, the most implicated drugs were allopurinol, hydroxychloroquine, and lamotrigine (18% for each), followed by antibiotics (sulfamide, secnidazole, cefalexin, cefotaxime, amoxicillin) (9.1% each)... Antiepileptics and antibiotics remain the most frequently implicated drugs. The hierarchy of inducing drugs varies depending on the type of toxicodermia, which may be explained by the genetic predisposition of patients, exogenous factors, and the pharmacodynamics of the drugs."
Clinical • Dermatology • Eosinophilia • Immunology • Steven-Johnson Syndrome
July 23, 2025
Drug Profile of Severe Toxicodermias in the Dermatology Department, Bab El Oued University Hospital, Algiers
(EADV 2025)
- "The most commonly implicated drugs in DRESS patients were antibiotics (38.88%) (amoxicillin +/− clavulanic acid, cefotaxime, ciprofloxacin, vancomycin, Bactrim, and azithromycin), followed by aromatic antiepileptics (33.33%) (carbamazepine, phenobarbital, lamotrigine, sodium valproate), and allopurinol (3 cases, 16.7%), with sulfasalazine and acetazolamide. In patients with Stevens-Johnson syndrome/Lyell's syndrome or a combination, the most implicated drugs were allopurinol, hydroxychloroquine, and lamotrigine (18% for each), followed by antibiotics (sulfamide, secnidazole, cefalexin, cefotaxime, amoxicillin) (9.1% each)... Antiepileptics and antibiotics remain the most frequently implicated drugs. The hierarchy of inducing drugs varies depending on the type of toxicodermia, which may be explained by the genetic predisposition of patients, exogenous factors, and the pharmacodynamics of the drugs"
Clinical • Dermatology • Eosinophilia • Immunology • Steven-Johnson Syndrome
August 27, 2025
Solvent polarity effects on the FTIR spectrum, and thermodynamic and electronic properties of metronidazole and its binding with antibacterial drugs: a DFT and molecular docking study.
(PubMed, RSC Adv)
- "Molecular docking of metronidazole with secnidazole, tizoxanide, and caffeine enhances the binding affinities, suggesting synergistic effects. In conclusion, this study emphasizes the importance of solvent polarity for optimizing the antibacterial properties of metronidazole and its molecular docking with other drugs."
Journal • Infectious Disease
August 16, 2025
Microfluidic paper-based fluorescent sensing device using citric acid derived carbon dots-tungsten sulfide spheres for onsite detection of secnidazole
(ACS-Fall 2025)
- "The US environmental protection agency's recommended UPLC method validated the detection efficiency of the proposed fluorescent sensor. The recoveries from UPLC and N-CDs@N-S-WS2 suggest that the present sensor can quantitatively analyze secnidazole in real samples."
Infectious Disease • Vaginitis
August 11, 2025
Preparation and characterization of a secnidazole-mandelic acid coamorphous system: enhanced dissolution profile, antibacterial properties, and theoretical druglikeness assessment.
(PubMed, Eur J Pharm Sci)
- "Importantly, the SNZ-MND (1:1) coamorphous exhibited enhanced antibacterial activity against Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa compared to the isolated compounds. These findings underscore the potential of the newly developed SNZ-MND coamorphous system as a promising antimicrobial binary composition with improved physicochemical and biological properties to be used in pharmaceutical dosage forms."
Journal • Infectious Disease • Pneumonia
June 06, 2025
Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole
(clinicaltrials.gov)
- P4 | N=1200 | Recruiting | Sponsor: Tulane University | Not yet recruiting ➔ Recruiting
Enrollment open • Gynecology • Infectious Disease • Vaginitis
May 26, 2025
Once Weekly Secnidazole Granules for the Treatment of Recurrent Bacterial Vaginosis
(ACOG 2025)
- "Twenty-four patients enrolled. Four patients were ineligible. Five patients failed initial therapy and were not eligible for suppressive therapy."
Infectious Disease • Vaginitis
May 22, 2025
Nitazoxanide and tizoxanide demonstrate high levels of in vitro activity against metronidazole-susceptible and metronidazole-resistant Trichomonas vaginalis clinical isolates.
(PubMed, Microbiol Spectr)
- "We compared the in vitro activity of the thiazolide nitazoxanide (NTZ) and its metabolite, tizoxanide (TIZ), with the activity of the Food and Drug Administration-approved 5-nitroimidazoles (metronidazole [MTZ], tinidazole [TDZ], and secnidazole [SEC]) against MTZ-susceptible and MTZ-resistant Trichomonas vaginalis clinical isolates. Additionally, comprehensive investigations can help inform public health strategies and reduce transmission rates. Ultimately, prioritizing research in this area is essential for improving patient outcomes and safeguarding reproductive health."
Journal • Preclinical • Infectious Disease
May 19, 2025
Repurposing Nitroimidazoles: A New Frontier in Combatting Bacterial Virulence and Quorum Sensing via In Silico, In Vitro, and In Vivo Insights.
(PubMed, Drug Dev Res)
- "In Vitro assays evaluated the effects of representative nitroimidazoles, metronidazole (MET) and secnidazole (SEC), on QS-controlled phenotypes, including violacein production in Chromobacterium violaceum and biofilm formation and protease activity in Pseudomonas aeruginosa, Acinetobacter baumannii, Salmonella enterica, and Proteus mirabilis...These findings position nitroimidazoles as dual-function agents; antimicrobial at bactericidal doses and anti-virulence at sub-MICs. Their validated efficacy across In Silico, In Vitro, and In Vivo models underscores their potential as adjunctive therapies, bridging the gap between drug repurposing and next-generation anti-infective development."
Journal • Preclinical • Infectious Disease
May 03, 2025
How to proceed with easily recrystallizing secnidazole in designing polyelectrolyte complex-based films for periodontitis treatment?
(PubMed, Eur J Pharm Sci)
- "The impact of utilized polymeric composition and polyelectrolyte complex structures as well as secnidazole form (crystalline/amorphous) on the films performance was observed. The increased temperature of drying enhanced secnidazole-polymers miscibility, which resulted in desirable drug loading improvement and also significantly prolonged secnidazole release to the artificial saliva."
Journal • Dental Disorders • Infectious Disease • Periodontitis
February 15, 2025
Simultaneous determination of five nitroimidazole antimicrobials in pharmaceuticals using HPLC-ESM and QAMS methods.
(PubMed, BMC Chem)
- "A green, rapid, and simple HPLC-External standard method (ESM) and a quantitative analysis of multi- components with a single-marker (QAMS) method were established for the simultaneous determination of five nitroimidazole antimicrobials (Metronidazole sodium chloride injection, Tinidazole injection, Ornidazole sodium chloride injection, Morinidazole sodium chloride injection, Secnidazole tablets) in pharmaceutical preparations...In addition, the analytical greenness (AGREE) and blue applicability grade index (BAGI) metric tools were used to evaluate the greenness and environmental friendliness of the developed methods. AGREE scores of QAMS and EMS were 0.66 and 0.59, and BAGI scored 82.5 and 77.5, respectively."
Journal
February 11, 2025
Low-cost and portable 3D-printed sensor for the determination of secnidazole in pharmaceutical and seized drug samples.
(PubMed, Anal Methods)
- "The obtained results were statistically similar (95% confidence level) to the values obtained by HPLC. These findings demonstrate that the 3D-printed electrodes developed in this study provide a cost-effective, facile, and highly sensitive platform for on-site SCZ analysis, presenting significant potential for future forensic applications."
Journal
January 18, 2025
Sunlight-mediated environmental risks of tinidazole in seawater: A neglected ocular toxicity of photolysis mixtures.
(PubMed, J Hazard Mater)
- "Herein, the photochemical reactivity of TNZ and four other typical nitroimidazoles (i.e., metronidazole, ornidazole, dimetridazole, and secnidazole) were quantified for multiple photoreactive species...This work reported the first comprehensive assessment of the photolysis-mediated environmental fate and secondary risks of TNZ in seawater. The findings highlighted the necessity of including complex photolysis mixtures under solar irradiation in future chemical risk assessments of marine environments."
Journal
October 28, 2024
Efficacy and safety of different drugs for the treatment of bacterial vaginosis: a systematic review and network meta-analysis.
(PubMed, Front Cell Infect Microbiol)
- "The clinical cure rate of oral ornidazole was better than clindamycin (RR 16.08; 95%-CI 1.72-150.47), Secnidazole (RR 8.17; 95%-CI 1.66-40.25) and probiotics. The clinical cure rate of vaginal application of sucrose was better than metronidazole (RR 1.12; 95%-CI 1.03-1.21) and metronidazole had a lower clinical cure rate than probiotics (RR 0.68; 95%-CI 0.52-0.88). The results of this systematic review and network meta-analysis suggest that ornidazole may be an effective alternative for the treatment of BV, and that sucrose and probiotics are potential BV treatments that need to be validated by more high-quality clinical studies in the future."
Clinical • Journal • Retrospective data • Review • Vaginitis
September 21, 2024
Development of purity certified reference materials to establish metrological traceability for the measurement of nitroimidazoles in agricultural products.
(PubMed, Anal Bioanal Chem)
- "Six nitroimidazole purity CRMs, including tinidazole (GBW09252), secnidazole (GBW09286), ronidazole (GBW09288), metronidazole (GBW(E)090755), dimetridazole (GBW(E)090819), and ornidazole (GBW(E)090820), were finally manufactured following authorization from China's State Administration for Market Regulation (SAMR). By using these CRMs, it is possible to improve the traceability, accuracy, and comparability of nitroimidazole measurements in a range of agricultural products, protecting public health."
Journal
September 16, 2024
Silver secnidazole nano-hybrid emulsion-based probiotics as a novel antifungal formula against multidrug-resistant vaginal pathogens.
(PubMed, Biotechnol Appl Biochem)
- "TEM photographs showed that C. auris cells treated with Ag-Secn-NHE-based probiotic formula revealed severe deformations and distored ultrastructural changes. furthermore, results indicated that the Gamma radiation up to 15 kGy increases production of Ag-Secn-NHE in comparison with non-irradiated one."
Journal • Candidiasis • Infectious Disease • Vaginitis
1 to 25
Of
99
Go to page
1
2
3
4